668 results on '"Weinmann, Arndt"'
Search Results
2. The role of resection in hepatocellular carcinoma BCLC stage B: A multi-institutional patient-level meta-analysis and systematic review
3. Amount of ascites impacts survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization advocating for volumetric assessment
4. Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
5. Evaluation of four chatbots in autoimmune liver disease: A comparative analysis
6. Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates
7. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
8. Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma
9. Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC
10. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
11. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
12. THU-457 Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitorbased therapy-first results from an international multicenter registry
13. THU-164-YI Evaluation of four chatbots in autoimmune liver disease: a comparative analysis
14. The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy
15. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer
16. Transjugular Portosystemic Stent Shunt: Impact of Right Atrial Pressure on Portal Venous Hemodynamics Within the First Week
17. Liver transplantation and BCLC classification: Limitations impede optimum treatment
18. NASH limits anti-tumour surveillance in immunotherapy-treated HCC
19. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis
20. Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B
21. Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging
22. Decision making for transjugular intrahepatic portosystemic stent shunt in refractory ascites and variceal bleeding: MELD, or not MELD, that is the question
23. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
24. Plasma exchange for treatment of a therapy‐related thrombotic microangiopathy in a patient with advanced hepatocellular carcinoma—A case report
25. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
26. Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis
27. Reduced Lipid Peroxidation Predicts Unfavorable Prognosis in Hepatocellular Carcinoma, but Not Intrahepatic Cholangiocarcinoma
28. Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC
29. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers
30. Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in an academic tertiary care centre
31. Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab
32. Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study
33. Dynamic evolution of the serum metabolome reflects human hepatocarcinogenesis
34. Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: outcome and safety profile
35. Poor sorafenib response in hepatocellular carcinoma patients is mediated by hypoxia-related 14-3-3 scaffolding proteins and induces a shift in tumor immune micromilieu
36. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma
37. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program
38. Sarcopenia as prognostic factor for survival after orthotopic liver transplantation
39. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients
40. Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
41. Mixed Hepatocellular Cholangiocarcinoma: A Comparison of Survival between Mixed Tumors, Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma from a Single Center
42. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
43. Immunonutritive scoring for survival stratification in patients undergoing transjugular intrahepatic portosystemic shunt: Results from a dual-center study
44. Poor response to sorafenib in HCC patients induces distinct immune-related signatures and is mediated by hypoxia-related 14-3-3 scaffolding proteins
45. Splenic volume – useful as prognostic factor in patients with portal hypertension after TIPS implantation?
46. Elderly Patients with Hepatocellular Carcinoma benefit from Liver Transplantation as much as younger ones
47. Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC—A Proof-of-Concept Study
48. Lipid Droplet-Associated Proteins Perilipin 1 and 2: Molecular Markers of Steatosis and Microvesicular Steatotic Foci in Chronic Hepatitis C
49. Regional differences in clinical presentation and prognosis of patients with post-sustained virologic response (SVR) hepatocellular carcinoma
50. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.